<DOC>
	<DOC>NCT02993107</DOC>
	<brief_summary>The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.</brief_summary>
	<brief_title>PALISADE Follow-on Study (ARC004)</brief_title>
	<detailed_description>This is an international, multicenter, open-label, 2-arm follow-on study of the safety, tolerability, and efficacy of AR101 in peanut-allergic individuals who have completed the ARC003 study. This study will explore alternative dosing regimens during extended maintenance with AR101.</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Completion of the ARC003 study Written informed consent and/or assent from subjects/guardians as appropriate Use of effective birth control by sexually active female subjects of childbearing potential Early discontinuation from the ARC003 study Meets any longitudinally applicable ARC003 study exclusion criteria (Group 2 only) Failure to tolerate â‰¥ 443 mg cumulative of peanut protein with no or mild symptoms in the ARC003 study Exit DBPCFC Any other condition that, in the opinion of the Investigator, precludes participation for reasons of safety</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AR101</keyword>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>CPNA (Characterized Peanut Allergen)</keyword>
	<keyword>OIT (oral immunotherapy)</keyword>
	<keyword>Peanut Allergy</keyword>
	<keyword>Allergy</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
	<keyword>Desensitization</keyword>
	<keyword>PALISADE</keyword>
</DOC>